Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bakris

Showing results (671-680 of 738) with videos related to

Pageof 74
Sort By:
Hypertension (Dallas, Tex. : 1979)|October 6, 2010
Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statementJohn M Flack, Domenic A Sica, George Bakris, et al.
Kidney Medicine|September 25, 2023
Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY AnalysisSylvia E Rosas, Luis M Ruilope, Stefan D Anker, et al.
JAMA|November 21, 2002
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trialJackson T Wright, George Bakris, Tom Greene, et al.
Journal of the American College of Cardiology|September 1, 2024
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW TrialRichard E Pratley, Katherine R Tuttle, Peter Rossing, et al.
Diabetes Care|October 16, 2016
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOSJan H Cornel, George L Bakris, Susanna R Stevens, et al.
Journal of the American Society of Hypertension : JASH|September 13, 2015
An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trialJohn M Flack, Deepak L Bhatt, David E Kandzari, et al.
Circulation|November 12, 2023
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and AlbuminuriaBrendon L Neuen, Hiddo J L Heerspink, Priya Vart, et al.
The Lancet. Diabetes & Endocrinology|November 28, 2024
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsSunil V Badve, Anika Bilal, Matthew M Y Lee, et al.
JAMA|December 6, 2003
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trialCarl J Pepine, Eileen M Handberg, Rhonda M Cooper-DeHoff, et al.
Journal of the American Heart Association|June 22, 2023
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE TrialsRobert A Fletcher, Clare Arnott, Patrick Rockenschaub, et al.
Pageof 74

Showing results (671-680 of 738) with videos related to

Sort By:
Pageof 74
Hypertension (Dallas, Tex. : 1979)|October 6, 2010
Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statementJohn M Flack, Domenic A Sica, George Bakris, et al.
Kidney Medicine|September 25, 2023
Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY AnalysisSylvia E Rosas, Luis M Ruilope, Stefan D Anker, et al.
JAMA|November 21, 2002
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trialJackson T Wright, George Bakris, Tom Greene, et al.
Journal of the American College of Cardiology|September 1, 2024
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW TrialRichard E Pratley, Katherine R Tuttle, Peter Rossing, et al.
Diabetes Care|October 16, 2016
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOSJan H Cornel, George L Bakris, Susanna R Stevens, et al.
Journal of the American Society of Hypertension : JASH|September 13, 2015
An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trialJohn M Flack, Deepak L Bhatt, David E Kandzari, et al.
Circulation|November 12, 2023
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and AlbuminuriaBrendon L Neuen, Hiddo J L Heerspink, Priya Vart, et al.
The Lancet. Diabetes & Endocrinology|November 28, 2024
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsSunil V Badve, Anika Bilal, Matthew M Y Lee, et al.
JAMA|December 6, 2003
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trialCarl J Pepine, Eileen M Handberg, Rhonda M Cooper-DeHoff, et al.
Journal of the American Heart Association|June 22, 2023
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE TrialsRobert A Fletcher, Clare Arnott, Patrick Rockenschaub, et al.
Pageof 74